Paper Details

  1. Home
  2. Paper Details

BRAF inhibitor and hairy cell leukemia-related transient acantholytic dermatosis.

Author: DurkinJohn R, ElwoodHillary, SinghAmy Garcia, Tchanque-FossuoCatherine N

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Grover disease (GD) is an acquired, transient or persistent acantholytic dermatosis. This report describes a 72-year-old man who developed GD after two weeks of treatment with vemurafenib without a MEK inhibitor. GD is increasingly reported as an immune-related adverse event in patients on BRAF inhibitor monotherapy. The patient was successfully treated with topical emollients, a corticosteroid, and temporary discontinuation of vemurafenib.
Paper Details　
Original Abstract of the Article :
Grover disease (GD) is an acquired, nonfamilial, nonimmune mediated, transient or persistent acantholytic dermatosis. Herein, we present a 72-year-old man who had clinical and histopathologic findings of GD following two weeks of treatment with vemurafenib without MEK inhibitor. The patient was succ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/32239892

データ提供：米国国立医学図書館（NLM）

A Skin Condition Linked to BRAF Inhibitors

The field of oncology is constantly evolving, with new treatments emerging to combat various cancers. This research delves into a side effect associated with BRAF inhibitors, a class of drugs used to target certain types of cancer. The study employed a case report approach to examine a patient who developed Grover disease (GD), a rare skin condition, after receiving vemurafenib, a BRAF inhibitor. They discovered that vemurafenib, when used without a MEK inhibitor, can paradoxically activate the MAPK signaling pathway, leading to keratinocyte proliferation and ultimately GD.

Understanding the Mechanism of BRAF Inhibitor-Induced GD

The study sheds light on the complex interplay between BRAF inhibitors and the immune system, highlighting the potential for paradoxical activation of signaling pathways. This information is valuable for clinicians to better manage the potential side effects of BRAF inhibitors.

A Reminder for Clinicians and Patients

This research underscores the importance of careful monitoring for skin conditions like GD when patients are on BRAF inhibitor therapy. Early detection and management can help minimize the impact on a patient's quality of life.

Dr.Camel's Conclusion

It seems that the use of BRAF inhibitors, like a camel crossing a vast desert, can lead to unexpected pathways. While they provide a lifeline for cancer patients, they also require careful consideration to avoid unintended consequences. This research highlights the importance of continuous learning and adaptation in the medical field.

Date :
  1. Date Completed 2020-05-22
  2. Date Revised 2020-05-22
Further Info :

Pubmed ID

32239892

DOI: Digital Object Identifier

32239892

Related Literature

Article Analysis
・Side Effects of vemurafenib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.